Evidence map›Paper›PMID 24983375›Full record

Trial reportPloS one2014

Inhibition of c3 convertase activity by hepatitis C virus as an additional lesion in the regulation of complement components.

Hangeun Kim, Keith Meyer, Adrian M Di Bisceglie, Ranjit Ray

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Interactions of viruses and the humoral innate immune response.Clinical immunology (Orlando, Fla.) · 2020
    Review
  6. In the Crosshairs: RNA Viruses OR Complement?Frontiers in immunology · 2020
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hangeun KimDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, United States of America.
Keith MeyerDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, United States of America.
Adrian M Di BisceglieDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, United States of America; Department of Molecular Microbiology & Immunology, Saint Louis University, St. Louis, Missouri, United States of America.
Ranjit RayDepartment of Internal Medicine, Saint Louis University, St. Louis, Missouri, United States of America; Department of Molecular Microbiology & Immunology, Saint Louis University, St. Louis, Missouri, United States of America.
Saint Louis University · US

Funding

Virology and Smallpox VaccinationsU54AI057160 · NIAID · WASHINGTON UNIVERSITY · PI RAY, RANJIT · 2003 to 2013
$80.9M
Mechanisms of Liver Disease Progression by Hepatitis C VirusR01DK080812 · NIDDK · SAINT LOUIS UNIVERSITY · PI RAY, RANJIT · 2009 to 2013
$1.6M
NIAID NIH HHS U54 AI057160NIAID NIH HHS U54-AI057160NIDDK NIH HHS DK080812NIDDK NIH HHS R01 DK080812
6 · The paper itself

Abstract

We have previously reported that in vitro HCV infection of cells of hepatocyte origin attenuates complement system at multiple steps, and attenuation also occurs in chronically HCV infected liver, irrespective of the disease stage. However, none of these regulations alone completely impaired complement pathways. Modulation of the upstream proteins involved in proteolytic processing of the complement cascade prior to convertase formation is critical in promoting the function of the complement system in response to infection. Here, we examined the regulation of C2 complement expression in hepatoma cells infected in vitro with cell culture grown virus, and validated our observations using randomly selected chronically HCV infected patient liver biopsy specimens. C2 mRNA expression was significantly inhibited, and classical C3 convertase (C4b2a) decreased. In separate experiments for C3 convertase function, C3b deposition onto bacterial membrane was reduced using HCV infected patient sera as compared to uninfected control, suggesting impaired C3 convertase. Further, iC3b level, a proteolytically inactive form of C3b, was lower in HCV infected patient sera, reflecting impairment of both C3 convertase and Factor I activity. The expression level of Factor I was significantly reduced in HCV infected liver biopsy specimens, while Factor H level remained unchanged or enhanced. Together, these results suggested that inhibition of C3 convertase activity is an additional cumulative effect for attenuation of complement system adopted by HCV for weakening innate immune response.

Indexed as

Gene Expression RegulationHepacivirusImmunity, InnateComplement C2Complement C3bComplement C3-C5 ConvertasesComplement Factor HFemaleHepatitis C, ChronicHumansLiverMaleRNA, MessengerComplement C2Complement C3bComplement C3-C5 ConvertasesComplement Factor HRNA, Messenger

Identifiers

PMID24983375
PMCPMC4077819
OpenAlexW2066744383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.